Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.56, read 2026-11-01
Ethical does not pass the values gate
Price60.88 USD
Fair value60.24
Ethical score10.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-18Read Accumulation55.93+8.9% to today ✓Markdown gives way to Accumulation after a 9% rise in 7 days
2026-10-11Read Markdown51.47+18.3% to today Distribution gives way to Markdown after a 28% slide in 6 weeks
2026-08-27Read Distribution71.59-15.0% to today ✓Accumulation gives way to Distribution with volume flow in agreement
2026-07-02Read Accumulation73.33-17.0% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Edison International holds its Accumulation at $60.88. Consolidating, no directional conviction, held for 23 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 23 days
Price at the screen
$60.88
Valuation
6.06 trailing · 9.05 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.61
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
44.19%
Below 33%
Interest-bearing debt is 44.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
4.88%
Below 33%
Cash held in interest-bearing accounts and securities is 4.9% of assets, under the one-third limit.
Pass
Receivables
1.72%
Below 49%
Money owed to the company is 1.7% of assets, under the 49% limit.
Pass
Revenue purity
0.97%
Below 5%
Only 1.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Edison International's business is in a permissible area, but its interest-bearing debt is about 44% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when EIX's ethical verdict changes
Today EIX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades above our $60.24 fair value estimate, moderate competitive moat.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 1.1% above the base estimate.
Where our models see it going: fair-value estimate $60.24, with a range of $51.98 to $84.46, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
California power with a debt overhang
Every time the lights flick on across southern California the cash moves through Edison's network, yet the company carries more debt than its regulated returns can safely handle.
We pass on Edison International. Revenue grows at 8 percent with an 18 percent profit margin and 19 percent return on equity, but the business fails our ethical screen on its debt ratio. A forward multiple of 11.9 times earnings and a moderate moat do not change the call.
Risk sits in the leverage that leaves little room for rate shocks or wildfire costs in its service area. Analysts rate it a hold with targets near the current price. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
EIX trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Accumulation$61.48+7.2%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (14 analysts) rates it hold, with a mean price target of $75.
2026-10-29Accumulation$57.35+2.5%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (14 analysts) rates it hold, with a mean price target of $75. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$55.93+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (14 analysts) rates it hold, with a mean price target of $75. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$55.93+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (14 analysts) rates it hold, with a mean price target of $75. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$55.93+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (14 analysts) rates it hold, with a mean price target of $75. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$55.93+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (14 analysts) rates it hold, with a mean price target of $75. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$55.93+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (14 analysts) rates it hold, with a mean price target of $75. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$55.93+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (14 analysts) rates it hold, with a mean price target of $75. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$55.93+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (14 analysts) rates it hold, with a mean price target of $75. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (14 analysts) rates it hold, with a mean price target of $75.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
